The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Low-Grade Gliomas
Open accessAbstract
Low-grade gliomas (LGGs) are a diverse group of primary brain tumors that often arise in young, otherwise healthy patients and generally have an indolent course with longer-term survival in comparison with high-grade gliomas. Treatment options include observation, surgery, radiation, chemotherapy, or a combined approach, and management is individualized based on tumor location, histology, molecular profile, and patient characteristics. Moreover, in this type of brain tumor with a relatively good prognosis and prolonged survival, the potential benefits of treatment must be carefully weighed against potential treatment-related risks. We review in this article current management strategies for LGG, including surgery, radiotherapy, and chemotherapy. In addition, the importance of profiling the genetic and molecular properties of LGGs in the development of targeted anticancer therapies is also reviewed. Finally, given the prevalence of these tumors in otherwise healthy young patients, the impact of treatment on neurocognitive function and quality of life is also evaluated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Erratum to: The 2007 WHO classification of tumours of the central nervous system
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-156115 · Cited by 4,442
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME
Sanai, N., & Berger, M. S. (2008) · Neurosurgery · doi:10.1227/01.neu.0000318159.21731.cf · Cited by 1,328
Primary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
van den Bent, M., Afra, D., de Witte, O., Hassel, M. B., Schraub, S., Hoang-Xuan, K., Malmström, P.-O., Collette, L., Piérart, M., Mirimanoff, R., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67070-5 · Cited by 1,035
Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis
Krueger, D. A., Care, M. M., Holland, K., Agricola, K., Tudor, C., Mangeshkar, P., Wilson, K. A., Byars, A., Sahmoud, T., & Franz, D. N. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001671 · Cited by 1,006
Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma
Pignatti, F., van den Bent, M., Curran, D., Debruyne, C., Sylvester, R., Therasse, P., Áfra, D., Cornu, P., Bolla, M., Vecht, C., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.121 · Cited by 955
Epidemiology and molecular pathology of glioma
Schwartzbaum, J. A., Fisher, J. L., Aldape, K. D., & Wrensch, M. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0289 · Cited by 949
Smith, J. S., Perry, A., Borell, T. J., Lee, H. K., O’Fallon, J., Hosek, S. M., Kimmel, D., Yates, A., Burger, P. C., Scheithauer, B. W., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.636 · Cited by 804
Douw, L., Klein, M., Fagel, S. S., van den Heuvel, J., Taphoorn, M. J., Aaronson, N. K., Postma, T. J., Vandertop, W. P., Mooij, J. J., Boerman, R. H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70204-2 · Cited by 757
Shaw, E., Arusell, R., Scheithauer, B., O’Fallon, J., O’Neill, B., Dinapoli, R., Nelson, D., Earle, J., Jones, C., Cascino, T., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.126 · Cited by 730
Karim, A. B. M. F., Maat, B., Hatlevoll, R., Menten, J., Rutten, E. H. J. M., Thomas, D. G. T., Mascarenhas, F., Horiot, J. C., Parvinen, L. M., van Reijn, M., et al. (1996) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00352-5 · Cited by 694
van den Bent, M., Wefel, J., Schiff, D., Taphoorn, M., Jaeckle, K., Junck, L., Armstrong, T., Choucair, A., Waldman, A., Gorlia, T., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70057-2 · Cited by 645
Jakola, A. S., Myrmel, K. S., Kloster, R., Torp, S. H., Lindal, S., Unsgård, G., & Solheim, O. (2012) · JAMA · doi:10.1001/jama.2012.12807 · Cited by 641
Mutations in CIC and FUBP1 Contribute to Human Oligodendroglioma
Bettegowda, C., Agrawal, N., Jiao, Y., Sausen, M., Wood, L. D., Hruban, R. H., Rodriguez, F. J., Cahill, D. P., McLendon, R., Riggins, G., et al. (2011) · Science · doi:10.1126/science.1210557 · Cited by 553
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas
Houillier, C., Wang, X., Kaloshi, G., Mokhtari, K., Guillevin, R., Laffaire, J., Paris, S., Boisselier, B., Idbaih, A., Laigle-Donadey, F., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181f96282 · Cited by 535
Seizure characteristics and control following resection in 332 patients with low-grade gliomas
Chang, E. F., Potts, M. B., Keles, G. E., Lamborn, K. R., Chang, S. M., Barbaro, N. M., & Berger, M. S. (2008) · Journal of Neurosurgery · doi:10.3171/jns/2008/108/2/0227 · Cited by 526
Claus, E. B., Horlacher, A., Hsu, L., Schwartz, R. B., Dello‐Iacono, D., Talos, F., Jolesz, F. A., & Black, P. M. (2005) · Cancer · doi:10.1002/cncr.20867 · Cited by 454
Andronesi, O. C., Kim, G. S., Gerstner, E., Batchelor, T., Tzika, A. A., Fantin, V. R., Vander Heiden, M. G., & Sorensen, A. G. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3002693 · Cited by 438
Self-citationSmith, J. S., Alderete, B., Minn, Y., Borell, T. J., Perry, A., Mohapatra, G., Hosek, S. M., Kimmel, D., O'Fallon, J., Yates, A., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202759 · Cited by 374
Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas
Dhermain, F. G., Hau, P., Lanfermann, H., Jacobs, A. H., & van den Bent, M. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70181-2 · Cited by 368
Shaw, E. G., Wang, M., Coons, S. W., Brachman, D. G., Buckner, J. C., Stelzer, K. J., Barger, G. R., Brown, P. D., Gilbert, M. R., & Mehta, M. P. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.8598 · Cited by 355
Dias-Santagata, D., Lam, Q., Vernovsky, K., Vena, N., Lennerz, J. K., Borger, D. R., Batchelor, T. T., Ligon, K. L., Iafrate, A. J., Ligon, A. H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017948 · Cited by 315
Self-citationYip, S., Butterfield, Y. S., Morozova, O., Chittaranjan, S., Blough, M. D., An, J., Birol, I., Chesnelong, C., Chiu, R., Chuah, E., et al. (2012) · The Journal of Pathology · doi:10.1002/path.2995 · Cited by 307
Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma
Quinn, J. A., Reardon, D. A., Friedman, A. H., Rich, J. N., Sampson, J. H., Provenzale, J. M., McLendon, R. E., Gururangan, S., Bigner, D. D., Herndon, J. E., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.009 · Cited by 258
Kiebert, G. M., Curran, D., Aaronson, N. K., Bolla, M., Menten, J., Rutten, E. H. J. M., Nordman, E., Silvestre, M. E., Pierart, M., & Karim, A. B. M. F. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00268-8 · Cited by 256
Extent of Surgical Resection Predicts Seizure Freedom in Low-Grade Temporal Lobe Brain Tumors
Englot, D. J., Han, S. J., Berger, M. S., Barbaro, N. M., & Chang, E. F. (2012) · Neurosurgery · doi:10.1227/neu.0b013e31823c3a30 · Cited by 234
MGMT methylation: A marker of response to temozolomide in low‐grade gliomas
Everhard, S., Kaloshi, G., Crinière, E., Benouaich‐Amiel, A., Lejeune, J., Marie, Y., Sanson, M., Kujas, M., Mokhtari, K., Hoang‐Xuan, K., et al. (2006) · Annals of Neurology · doi:10.1002/ana.21044 · Cited by 215
Sorensen, A. G., Batchelor, T. T., Wen, P. Y., Zhang, W.-T., & Jain, R. K. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1204 · Cited by 192
Self-citationLeu, S., von Felten, S., Frank, S., Vassella, E., Vajtai, I., Taylor, E., Schulz, M., Hutter, G., Hench, J., Schucht, P., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos317 · Cited by 192
Central Nervous System Cancers, Version 1.2015
Nabors, L. B., Portnow, J., Ammirati, M., Baehring, J., Brem, H., Brown, P., Butowski, N., Chamberlain, M. C., Fenstermaker, R. A., Friedman, A., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0148 · Cited by 178
Self-citationManagement of Low-Grade Glioma
Pouratian, N., & Schiff, D. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0105-7 · Cited by 174
Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?
Hartmann, C., Hentschel, B., Tatagiba, M., Schramm, J., Schnell, O., Seidel, C., Stein, R., Reifenberger, G., Pietsch, T., von Deimling, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3194 · Cited by 171
CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas
Sahm, F., Koelsche, C., Meyer, J., Pusch, S., Lindenberg, K., Mueller, W. C., Herold‐Mende, C. C., von Deimling, A., & Hartmann, C. J. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-0993-5 · Cited by 168
Grimm, S. A., & Chamberlain, M. C. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0346-3 · Cited by 160
Outcome in adult low-grade glioma: The impact of prognostic factors and treatment
Schiff, D., Brown, P. D., & Giannini, C. (2007) · Neurology · doi:10.1212/01.wnl.0000277271.47601.a1 · Cited by 133
Fan, G., Deng, Q. L., Wu, Z. H., & Guo, Q. (2006) · British Journal of Radiology · doi:10.1259/bjr/25349497 · Cited by 117
Metabolic imaging of low-grade gliomas with three-dimensional magnetic resonance spectroscopy
Pirzkall, A., Nelson, S. J., McKnight, T. R., et al. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02869-9 · Cited by 116
Surgery Insight: the role of surgery in the management of low-grade gliomas
Pouratian, N., Asthagiri, A. R., Jagannathan, J., Shaffrey, M. E., & Schiff, D. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0634 · Cited by 108
Quality of life in low-grade glioma patients receiving temozolomide
Liu, R., Solheim, K. N., Polley, M. C., Lamborn, K. R., Page, M., Fedoroff, A., Rabbitt, J. E., Butowski, N. A., Prados, M. D., & Chang, S. M. (2008) · Neuro-Oncology · doi:10.1215/15228517-2008-063 · Cited by 95
Clinical Outcome of Supratentorial Astrocytoma WHO Grade II
Peraud, A., Ansari, H., Bise, K., & Reulen, H.-J. (1998) · Acta Neurochirurgica · doi:10.1007/s007010050241 · Cited by 81
Youland, R. S., Brown, P. D., Giannini, C., Parney, I. F., Uhm, J. H., & Laack, N. N. (2012) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31825d580a · Cited by 57
Baumert, B. G., Mason, W. P., Ryan, G. F., Bromberg, J. E. C., van den Bent, M. J., Hoang‐Xuan, K., Brandes, A. A., Kantor, G., TAPHOORN, M. J. B., Hassel, M. B., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2007 · Cited by 50
Aryan, H. E., Meltzer, H. S., Lu, D. C.-T., Ozgur, B. M., Levy, M. L., & Bruce, D. A. (2004) · Child s Nervous System · doi:10.1007/s00381-004-1002-7 · Cited by 34
Late neurocognitive decline after radiotherapy for low-grade glioma
Khasraw, M., & Lassman, A. B. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.194 · Cited by 31
Low-grade glioma: a challenge in therapeutic options: the role of radiotherapy
Baumert, B. G., & Stupp, R. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn434 · Cited by 29
Fisher, B. J., Lui, J., Macdonald, D., Lesser, G. J., Coons, S. W., Brachman, D. G., Ryu, S., Werner‐Wasik, M., Bahary, J.-P., Hu, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.2008 · Cited by 25
Cited by
CGCG clinical practice guidelines for the management of adult diffuse gliomas
Jiang, T., Mao, Y., Ma, W., Mao, Q., You, Y., Yang, X., Jiang, C., Kang, C., Li, X., Chen, L., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.024 · Cited by 607
Boron neutron capture therapy: Current status and future perspectives
Dymova, M. A., Taskaev, S. Y., Richter, V. A., & Kuligina, E. V. (2020) · Cancer Communications · doi:10.1002/cac2.12089 · Cited by 339
Ferraris, C., Cavalli, R., Panciani, P. P., & Battaglia, L. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s231479 · Cited by 131
Prabhudesai, S., Wang, N. C., Ahluwalia, V., Huan, X., Bapuraj, J. R., Banovic, N., & Rao, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.740353 · Cited by 13
Rimmer, B., Dutton, L., Lewis, J., Burns, R., Gallagher, P., Williams, S., Araujo-Soares, V., Finch, T., & Sharp, L. (2020) · BMJ Open · doi:10.1136/bmjopen-2020-041465 · Cited by 12
Metadata
- Authors
- Forst, D. A., Nahed, B. V., Loeffler, J. S., & Batchelor, T. T.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03-24
- Volume
- 19
- Issue
- 4
- Pages
- 403-413
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2123046490
- Cited by
- 253
- References
- 49
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.